9 results on '"Pierre, Duraffour"'
Search Results
2. Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis
- Author
-
Xavier Mariette, Antoine Rousseau, Hubert Marotte, Eric Gabison, Raphaele Seror, Gaetane Nocturne, Isabelle Bonnet, Pierre Duraffour, Jacques Pouchot, and Chi Duc Nguyen
- Subjects
Medicine - Abstract
Objective Peripheral ulcerative keratitis (PUK) is a rare but severe ocular complication of rheumatoid arthritis (RA). It can be considered as an ocular manifestation of rheumatoid vasculitis (RV). Our case series aimed to evaluate the efficacy of rituximab (RTX) for PUK occurring in patients with RA.Methods Study population were patients with RA-associated PUK treated with RTX 1000 mg on days 1 and 15 at least once after the diagnosis. We identified patients referred to the rheumatology and ophthalmology departments of our hospital between February 2014 and June 2020. We also included patients referred by their specialist after being contacted through the Club Rhumatismes et Inflammation. Demographic data and clinical and biological features were retrospectively collected.Results We included seven patients (three men and four women, median age 58 years). All but one had a long-standing RA with a median disease duration of 13.9 years (IQR 0–30.2). RA was erosive in six out of seven patients. All patients had rheumatoid factors and anticitrullinated peptides antibodies were positive in six of them. PUK was complicated by corneal perforation in three patients and required surgery. After a median follow-up of 29.8 months (IQR 5–75), corneal inflammation was controlled in all patients. PUK recurred in one patient, 8 months after a single infusion of RTX. 71% of the patients presented a good articular response. No patient developed other manifestations of RV. No serious adverse event related to RTX was observed.Conclusion RTX appears to be an efficient and safe therapeutic option in the treatment of RA-associated PUK.
- Published
- 2021
- Full Text
- View/download PDF
3. Transscleral filtration revealing a chorioretinal coloboma
- Author
-
Benjamin Scemla, Quentin Duroi, Pierre Duraffour, Vaël Souedan, and Antoine P. Brézin
- Subjects
Transscleral filtration ,Chorioretinal coloboma ,Ocular hypotony ,Ophthalmology ,RE1-994 - Abstract
Purpose: We report the case of a 19-year-old patient who presented with an ocular hypotony due to a transscleral filtration through an isolated congenital chorioretinal coloboma in his right eye. Observations: The initial examination showed a decimal best corrected visual acuity (BCVA) decreased to 0.7 and a marked hypotony. A localized infero-nasal chemosis and a conjunctival hyperemia were observed. The fundus examination showed chorioretinal folds and an edematous disc. In the infero-nasal retinal periphery, a chorioretinal coloboma was seen with a full-thickness scleral defect. Ultrasound biomicroscopy showed the area of the coloboma through which the percolation of fluid occurred. Conclusions and importance: A favorable outcome was observed within 6 weeks and BCVA improved to 1.0 three months later. The intraocular pressure (IOP) increased to 11 mmHg, but the bleb-like filtration could still be seen together with some persistent chorioretinal folds. Ultrasound Biomicroscopy (UBM) imaging was helpful to understand the mechanism of this uncommon complication of a coloboma.
- Published
- 2021
- Full Text
- View/download PDF
4. Hypervirulent Klebsiella Pneumoniae, an Emerging Cause of Endogenous Endophthalmitis in A French Center: A Comparative Cohort Study
- Author
-
Jean-Philippe Martellosio, Nabil Gastli, Rebecca Farhat, Asmaa Tazi, Pierre Duraffour, Benjamin Rossi, Etienne Canouï, Caroline Morbieu, Annick Billoët, Luc Mouthon, Claire Poyart, Antoine Brézin, and Paul Legendre
- Subjects
Ophthalmology ,Immunology and Allergy - Published
- 2022
5. De Novo Vogt-Koyanagi-Harada Disease following Covid-19 Vaccine: A Case Report and Literature Overview
- Author
-
Jean-Baptiste Brunet de Courssou, Mylène Tisseyre, Jérôme Hadjadj, Laurent Chouchana, Florent Broca, Benjamin Terrier, Pierre Duraffour, and Soledad Henriquez
- Subjects
Ophthalmology ,Immunology and Allergy - Published
- 2022
6. Hypervirulent
- Author
-
Jean-Philippe, Martellosio, Nabil, Gastli, Rebecca, Farhat, Asmaa, Tazi, Pierre, Duraffour, Benjamin, Rossi, Etienne, Canouï, Caroline, Morbieu, Annick, Billoët, Luc, Mouthon, Claire, Poyart, Antoine, Brézin, and Paul, Legendre
- Abstract
EE cases were retrospectively studied between January 2014 and January 2021. KP EE cases were analyzed to assess clinical, microbiological features, and outcome.Among the 33 EE cases identified, the first causative agent (24%,KP is an emerging cause of EE in a French center, consistently associated with liver abscesses, frequent cerebral involvement, and predominance of hvKP strains.
- Published
- 2022
7. Birdshot Chorioretinopathy: A Review
- Author
-
Elodie, Bousquet, Pierre, Duraffour, Louis, Debillon, Swathi, Somisetty, Dominique, Monnet, and Antoine P, Brézin
- Subjects
General Medicine - Abstract
Birdshot chorioretinopathy (BSCR) is a bilateral chronic inflammation of the eye with no extraocular manifestations. BSCR affects middle-aged individuals from European descent and is strongly associated with the human leucocyte antigen (HLA)-A29 allele. The immune mechanisms involved are not fully understood, but recent advances have shown the role of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) in disease pathogenesis. Multimodal imaging, including fluorescein angiography, indocyanine angiography, fundus autofluorescence, and optical coherence tomography, are useful in confirming the diagnosis and monitoring disease activity. Visual field testing is also important to assess the disease progression. To date, there is no consensus for optimal treatment regimen and duration. Local and systemic corticosteroids can be used for short periods, but immunosuppressive or biological therapies are usually needed for the long-term management of the disease. Here, we will review publications focused on birdshot chorioretinopathy to give an update on the pathophysiology, the multimodal imaging, and the treatment of the disease.
- Published
- 2022
8. Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis
- Author
-
Pierre Duraffour, Eric E. Gabison, Xavier Mariette, Isabelle Bonnet, Jacques Pouchot, Raphaèle Seror, Gaetane Nocturne, Antoine Rousseau, Chi Duc Nguyen, and Hubert Marotte
- Subjects
Male ,medicine.medical_specialty ,rheumatoid ,Immunology ,Arthritis ,Rheumatoid Arthritis ,Rheumatoid Vasculitis ,Corneal inflammation ,Arthritis, Rheumatoid ,03 medical and health sciences ,0302 clinical medicine ,rituximab ,Rheumatology ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,Adverse effect ,Corneal Ulcer ,Retrospective Studies ,030203 arthritis & rheumatology ,business.industry ,Middle Aged ,medicine.disease ,arthritis ,Rheumatoid arthritis ,030221 ophthalmology & optometry ,Rheumatoid vasculitis ,Medicine ,Rituximab ,Female ,systemic vasculitis ,business ,Systemic vasculitis ,medicine.drug - Abstract
ObjectivePeripheral ulcerative keratitis (PUK) is a rare but severe ocular complication of rheumatoid arthritis (RA). It can be considered as an ocular manifestation of rheumatoid vasculitis (RV). Our case series aimed to evaluate the efficacy of rituximab (RTX) for PUK occurring in patients with RA.MethodsStudy population were patients with RA-associated PUK treated with RTX 1000 mg on days 1 and 15 at least once after the diagnosis. We identified patients referred to the rheumatology and ophthalmology departments of our hospital between February 2014 and June 2020. We also included patients referred by their specialist after being contacted through the Club Rhumatismes et Inflammation. Demographic data and clinical and biological features were retrospectively collected.ResultsWe included seven patients (three men and four women, median age 58 years). All but one had a long-standing RA with a median disease duration of 13.9 years (IQR 0–30.2). RA was erosive in six out of seven patients. All patients had rheumatoid factors and anticitrullinated peptides antibodies were positive in six of them. PUK was complicated by corneal perforation in three patients and required surgery. After a median follow-up of 29.8 months (IQR 5–75), corneal inflammation was controlled in all patients. PUK recurred in one patient, 8 months after a single infusion of RTX. 71% of the patients presented a good articular response. No patient developed other manifestations of RV. No serious adverse event related to RTX was observed.ConclusionRTX appears to be an efficient and safe therapeutic option in the treatment of RA-associated PUK.
- Published
- 2021
9. Transscleral filtration revealing a chorioretinal coloboma
- Author
-
Antoine P. Brézin, Pierre Duraffour, Quentin Duroi, Vaël Souedan, and Benjamin Scemla
- Subjects
Chorioretinal coloboma ,Chemosis ,medicine.medical_specialty ,Intraocular pressure ,genetic structures ,Ultrasound biomicroscopy ,Case Report ,Fundus (eye) ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,lcsh:Ophthalmology ,Ophthalmology ,medicine ,Transscleral filtration ,Coloboma ,business.industry ,Retinal ,medicine.disease ,eye diseases ,chemistry ,lcsh:RE1-994 ,Ocular hypotony ,030221 ophthalmology & optometry ,sense organs ,medicine.symptom ,Complication ,business ,030217 neurology & neurosurgery - Abstract
Purpose We report the case of a 19-year-old patient who presented with an ocular hypotony due to a transscleral filtration through an isolated congenital chorioretinal coloboma in his right eye. Observations The initial examination showed a decimal best corrected visual acuity (BCVA) decreased to 0.7 and a marked hypotony. A localized infero-nasal chemosis and a conjunctival hyperemia were observed. The fundus examination showed chorioretinal folds and an edematous disc. In the infero-nasal retinal periphery, a chorioretinal coloboma was seen with a full-thickness scleral defect. Ultrasound biomicroscopy showed the area of the coloboma through which the percolation of fluid occurred. Conclusions and importance A favorable outcome was observed within 6 weeks and BCVA improved to 1.0 three months later. The intraocular pressure (IOP) increased to 11 mmHg, but the bleb-like filtration could still be seen together with some persistent chorioretinal folds. Ultrasound Biomicroscopy (UBM) imaging was helpful to understand the mechanism of this uncommon complication of a coloboma.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.